B. Raman
University of Adelaide
7 Papers
7 Citations
B. Raman is an academic researcher from University of Adelaide. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 6, co-authored 7 publications. Previous affiliations of B. Raman include Queen Elizabeth II Hospital.
Chat about Author
Papers
Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial [N-acetylcysteine in Acute Myocardial Infarction])
Sivabaskari Pasupathy,Rosanna Tavella,Suchi Grover,B. Raman,Nathan E.K. Procter,Yang Timothy Du,Gnanadevan Mahadavan,Irene Stafford,Tamila Heresztyn,Andrew P. Holmes,Christopher Zeitz,Margaret Arstall,Joseph B. Selvanayagam,John D. Horowitz,John F. Beltrame +14 more
TL;DR: High-dose intravenous NAC administered with low- dose intravenous nitroglycerin is associated with reduced infarct size in patients with ST-segment–elevation myocardial infarction undergoing percutaneous coronary intervention.
124
Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome
Sven Y. Surikow,Thanh H Nguyen,Irene Stafford,Matthew Chapman,Sujith Chacko,Kuljit Singh,Giovanni Licari,B. Raman,Darren J. Kelly,Yuan Zhang,Mark T. Waddingham,Doan T.M. Ngo,Alexander P. Bate,S. Chua,Michael P. Frenneaux,John D. Horowitz +15 more
TL;DR: This article showed that pre-treatment with an inhibitor of poly(ADP-ribose) polymerase-1 ameliorated contractile abnormalities in Takotsubo syndrome (TS) patients.
Clopidogrel “resistance”: Pre- vs post-receptor determinants
Nicola L. Hurst,Vivek B. Nooney,B. Raman,Yuliy Y. Chirkov,R. De Caterina,John D. Horowitz,John D. Horowitz +6 more
TL;DR: It is speculated that the possibility that non-genetic causes of clopidogrel "resistance" may arise from impairments of the intracellular signaling cascade initiated by P2Y12 receptor inhibition may facilitate the development of optimal therapeutic strategies for high-risk cardiovascular patients.